Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	1,903	2,007	2,670	1,919	2,487	2,671
Other Revenue	6.43	4.7	7.33	3.42	4.54	4.5
Revenue	1,910	2,012	2,677	1,922	2,491	2,675
Revenue Growth	-17.54%	-24.86%	39.27%	-22.84%	-6.88%	37.15%
Cost of Revenue	443.56	440.4	520.26	390.89	440.36	402.12
Gross Profit	1,466	1,571	2,157	1,531	2,051	2,273
Selling, General & Admin	540.81	633.15	881.19	787.89	838.78	729.46
Research & Development	204.08	198.45	240.09	245.38	253.91	173.77
Other Operating Expenses	43.67	32.17	37.29	24.61	33.72	39.56
Operating Expenses	788.99	862.83	1,159	1,048	1,124	949.55
Operating Income	677.33	708.59	997.98	482.98	926.66	1,324
Interest Expense	-51.47	-53.51	-63.71	-54.33	-36.04	-8.91
Interest & Investment Income	67.95	67.95	73.09	87.96	63.79	56.5
Currency Exchange Gain (Loss)	-5.15	-2.17	0.78	1.22	1.07	-0.81
Other Non Operating Income (Expenses)	17.95	2.01	-1.73	-2.12	-0.5	-5.34
EBT Excluding Unusual Items	706.61	722.86	1,006	515.71	954.97	1,365
Impairment of Goodwill	-	-	-5.2	-25.61	-6.26	-
Gain (Loss) on Sale of Investments	-2.72	0.01	1.02	-	-0.01	0.01
Gain (Loss) on Sale of Assets	1.22	-0.08	3.64	6.72	0.86	0.98
Asset Writedown	-57.12	-53.59	-1.04	-1.46	-1.61	-1.15
Other Unusual Items	-2.63	-9.08	2.13	25.66	68.85	42.14
Pretax Income	645.36	660.13	1,007	521.02	1,017	1,407
Income Tax Expense	119.36	128.46	192.78	95.3	135.86	211.38
Earnings From Continuing Operations	525.99	531.67	814.19	425.72	880.95	1,196
Minority Interest in Earnings	-0.92	1.15	6.01	10.77	8.62	0.97
Net Income	525.07	532.82	820.2	436.49	889.56	1,197
Net Income to Common	525.07	532.82	820.2	436.49	889.56	1,197
Net Income Growth	-20.13%	-35.04%	87.91%	-50.93%	-25.67%	36.74%
Shares Outstanding (Basic)	780	772	781	794	794	803
Shares Outstanding (Diluted)	780	772	781	794	794	803
Shares Change	0.95%	-1.14%	-1.57%	-0.08%	-1.12%	-0.89%
EPS (Basic)	0.67	0.69	1.05	0.55	1.12	1.49
EPS (Diluted)	0.67	0.69	1.05	0.55	1.12	1.49
EPS Growth	-20.88%	-34.29%	90.91%	-50.89%	-24.83%	37.96%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Free Cash Flow	424.25	548.63	815.85	669.49	407.91	712
Free Cash Flow Per Share	0.54	0.71	1.04	0.84	0.51	0.89
Dividend Per Share	0.520	0.520	0.800	0.400	0.670	0.900
Dividend Growth	-35.00%	-35.00%	100.00%	-40.30%	-25.56%	36.36%
Gross Margin	76.78%	78.11%	80.57%	79.67%	82.33%	84.97%
Operating Margin	35.47%	35.22%	37.28%	25.12%	37.19%	49.48%
Profit Margin	27.49%	26.48%	30.64%	22.71%	35.70%	44.73%
Free Cash Flow Margin	22.21%	27.27%	30.47%	34.83%	16.37%	26.61%
EBITDA	793.28	825.76	1,122	573.43	995.72	1,373
EBITDA Margin	41.54%	41.05%	41.90%	29.83%	39.97%	51.32%
D&A For EBITDA	115.94	117.16	123.92	90.44	69.07	49.25
EBIT	677.33	708.59	997.98	482.98	926.66	1,324
EBIT Margin	35.47%	35.22%	37.28%	25.12%	37.19%	49.48%
Effective Tax Rate	18.50%	19.46%	19.14%	18.29%	13.36%	15.02%
Revenue as Reported	1,910	2,012	2,677	1,922	2,491	2,675